Regeneron Faces Setback with Eylea Sales Decline and Regulatory Delays

Regeneron shares fell 5% on the stock market due to a decline in Eylea sales and regulatory delays, overshadowing the company's reported earnings beat. Eylea's sales and regulatory issues weigh heavily on REGN stock. Investors are now focusing on upcoming data related to the company's products for more relevant information.

Regeneron Pharmaceuticals shares fell approximately 6% on April 29 despite reporting Q1 2026 total revenues that rose 19% year-over-year to $3.605 billion, beating analyst estimates. The selloff was driven by a deteriorating Eylea franchise: combined U.S. EYLEA and EYLEA HD net sales fell 10% to $941 million — the first time the combined total dropped below $1 billion since Q2 2018. Legacy EYLEA volumes declined due to competitive pressure from biosimilars and patient migration, partially offset by EYLEA HD growing 52% to $468 million.

The regulatory headwind compounded investor concern: the FDA failed to meet its April 2026 target action date on Regeneron's application to add a second contract manufacturing site for the pre-filled syringe version of EYLEA HD. This manufacturing approval delay introduces supply risk and pushes out the timeline for margin improvement associated with the pre-filled syringe form factor, which carries higher convenience and pricing potential.

Despite the near-term headwinds, REGN reported non-GAAP net income up 12% to $1.04 billion and non-GAAP diluted EPS up 15% to $9.47. The company approved a new $3 billion share repurchase program, signaling management confidence in the long-term trajectory. The key question for investors is whether EYLEA HD's 52% growth rate is sufficient to absorb the legacy EYLEA erosion and restore the franchise to growth — a calculus that will become clearer over the next two to three quarters.

Related Stocks

REGN